25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

LYRA (Lyra Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Lyra Therapeutics Inc together

I guess you are interested in Lyra Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Lyra Therapeutics Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Lyra Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Lyra Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Lyra Therapeutics Inc

I send you an email if I find something interesting about Lyra Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Lyra Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Lyra Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.92
Expected worth in 1 year
$4.63
How sure are you?
31.8%

+ What do you gain per year?

Total Gains per Share
$1.71
Return On Investment
18.4%

For what price can you sell your share?

Current Price per Share
$9.31
Expected price per share
$4.1 - $125.00
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Lyra Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$9.31
Intrinsic Value Per Share
$-381.52 - $-453.05
Total Value Per Share
$-378.60 - $-450.13

2.2. Growth of Lyra Therapeutics Inc (5 min.)




Is Lyra Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$3.8m$87.4m-$70.6m-421.5%

How much money is Lyra Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$19.8m-$17.2m-$2.6m-13.4%
Net Profit Margin-6,015.2%-5,222.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Lyra Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#665 / 884

Most Revenue
#519 / 884

Most Profit
#650 / 884

Most Efficient
#814 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Lyra Therapeutics Inc?

Welcome investor! Lyra Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Lyra Therapeutics Inc.

First you should know what it really means to hold a share of Lyra Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Lyra Therapeutics Inc is $9.31. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lyra Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lyra Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.92. Based on the TTM, the Book Value Change Per Share is $0.43 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lyra Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-6.45-69.3%-15.00-161.1%-0.31-3.4%-5.25-56.4%-3.42-36.8%-3.16-33.9%
Usd Book Value Change Per Share-5.83-62.6%0.434.6%-0.15-1.6%0.060.7%0.667.1%0.131.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-5.83-62.6%0.434.6%-0.15-1.6%0.060.7%0.667.1%0.131.4%
Usd Price Per Share0.13-0.22-4.87-3.01-5.36-4.87-
Price to Earnings Ratio0.00--0.01--3.95--2.10--2.69--2.45-
Price-to-Total Gains Ratio-0.02--0.02-12.18-48.54-24.31-24.31-
Price to Book Ratio0.04-0.02-3.24-1.59-1.70-1.54-
Price-to-Total Gains Ratio-0.02--0.02-12.18-48.54-24.31-24.31-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.31
Number of shares107
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.430.66
Usd Total Gains Per Share0.430.66
Gains per Quarter (107 shares)45.7670.43
Gains per Year (107 shares)183.05281.74
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101831730282272
203663560563554
305495390845836
40732722011271118
50915905014091400
6010981088016901682
7012811271019721964
8014641454022542246
9016471637025362528
10018301820028172810

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.022.00.00.0%0.022.00.00.0%
Book Value Change Per Share1.03.00.025.0%5.07.00.041.7%6.014.00.030.0%7.015.00.031.8%7.015.00.031.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%6.014.00.030.0%7.015.00.031.8%7.015.00.031.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Lyra Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---5.8260.428-1462%-0.146-97%0.063-9334%0.658-985%0.133-4488%
Book Value Per Share--2.92212.650-77%1.627+80%5.604-48%5.410-46%4.506-35%
Current Ratio--2.9563.401-13%5.990-51%5.931-50%8.173-64%7.832-62%
Debt To Asset Ratio--0.9310.792+18%0.336+178%0.453+106%0.353+164%0.531+75%
Debt To Equity Ratio--13.5445.785+134%0.532+2447%2.208+513%1.443+839%1.359+897%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---20542007.160-9088563.890-56%332021938.475-106%179216214.243-111%171178731.839-112%171178731.839-112%
Eps---6.449-15.002+133%-0.312-95%-5.247-19%-3.423-47%-3.159-51%
Ev To Ebitda Ratio--0.5810.261+123%-4.657+902%-2.698+564%-3.754+746%-3.754+746%
Ev To Sales Ratio---28.063-12.705-55%268.891-110%441.866-106%544.668-105%544.668-105%
Free Cash Flow Per Share---6.671-10.674+60%-0.328-95%-3.781-43%-2.518-62%-2.333-65%
Free Cash Flow To Equity Per Share---6.671-10.695+60%0.057-11777%-3.676-45%-2.096-69%-1.843-72%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---453.049----------
Intrinsic Value_10Y_min---381.520----------
Intrinsic Value_1Y_max---19.532----------
Intrinsic Value_1Y_min---19.170----------
Intrinsic Value_3Y_max---78.399----------
Intrinsic Value_3Y_min---74.448----------
Intrinsic Value_5Y_max---161.033----------
Intrinsic Value_5Y_min---147.770----------
Market Cap12338915.400+99%166992.840286936.110-42%275038438.475-100%137630964.243-100%125609381.839-100%114190347.126-100%
Net Profit Margin---46.705-60.152+29%-52.220+12%-154.982+232%-134.997+189%-122.725+163%
Operating Margin---49.011-43.735-11%-55.097+12%-147.696+201%-130.999+167%-119.090+143%
Operating Ratio--49.31155.603-11%67.719-27%158.085-69%159.938-69%145.398-66%
Pb Ratio3.187+99%0.0430.024+82%3.239-99%1.593-97%1.696-97%1.542-97%
Pe Ratio-0.361-7289%-0.005-0.005+3%-3.952+80814%-2.104+42968%-2.691+54987%-2.446+49979%
Price Per Share9.310+99%0.1260.217-42%4.870-97%3.013-96%5.360-98%4.873-97%
Price To Free Cash Flow Ratio-0.349-7289%-0.005-0.005+9%-3.713+78548%-2.332+49285%-2.209+46692%-2.008+42439%
Price To Total Gains Ratio-1.598-7289%-0.022-0.018-16%12.179-100%48.540-100%24.311-100%24.311-100%
Quick Ratio--2.7674.160-33%9.947-72%8.176-66%9.409-71%8.950-69%
Return On Assets---0.152-0.244+61%-0.130-15%-0.169+12%-0.152+0%-0.156+3%
Return On Equity---2.207-1.321-40%-0.201-91%-0.566-74%-0.410-81%-0.400-82%
Total Gains Per Share---5.8260.428-1462%-0.146-97%0.063-9334%0.658-985%0.133-4488%
Usd Book Value--3872000.00016765500.000-77%87435000.000-96%63991583.333-94%62241900.000-94%51153863.636-92%
Usd Book Value Change Per Share---5.8260.428-1462%-0.146-97%0.063-9334%0.658-985%0.133-4488%
Usd Book Value Per Share--2.92212.650-77%1.627+80%5.604-48%5.410-46%4.506-35%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---20542007.160-9088563.890-56%332021938.475-106%179216214.243-111%171178731.839-112%171178731.839-112%
Usd Eps---6.449-15.002+133%-0.312-95%-5.247-19%-3.423-47%-3.159-51%
Usd Free Cash Flow---8842000.000-14146750.000+60%-18265000.000+107%-14757750.000+67%-11859450.000+34%-11146000.000+26%
Usd Free Cash Flow Per Share---6.671-10.674+60%-0.328-95%-3.781-43%-2.518-62%-2.333-65%
Usd Free Cash Flow To Equity Per Share---6.671-10.695+60%0.057-11777%-3.676-45%-2.096-69%-1.843-72%
Usd Market Cap12338915.400+99%166992.840286936.110-42%275038438.475-100%137630964.243-100%125609381.839-100%114190347.126-100%
Usd Price Per Share9.310+99%0.1260.217-42%4.870-97%3.013-96%5.360-98%4.873-97%
Usd Profit---8547000.000-19882500.000+133%-17219250.000+101%-17339916.667+103%-13810350.000+62%-12945090.909+51%
Usd Revenue--183000.000296250.000-38%420000.000-56%337666.667-46%485200.000-62%441090.909-59%
Usd Total Gains Per Share---5.8260.428-1462%-0.146-97%0.063-9334%0.658-985%0.133-4488%
 EOD+5 -3MRQTTM+13 -24YOY+10 -273Y+9 -285Y+9 -2810Y+9 -28

3.3 Fundamental Score

Let's check the fundamental score of Lyra Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.361
Price to Book Ratio (EOD)Between0-13.187
Net Profit Margin (MRQ)Greater than0-46.705
Operating Margin (MRQ)Greater than0-49.011
Quick Ratio (MRQ)Greater than12.767
Current Ratio (MRQ)Greater than12.956
Debt to Asset Ratio (MRQ)Less than10.931
Debt to Equity Ratio (MRQ)Less than113.544
Return on Equity (MRQ)Greater than0.15-2.207
Return on Assets (MRQ)Greater than0.05-0.152
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Lyra Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.013
Ma 20Greater thanMa 5013.604
Ma 50Greater thanMa 1009.229
Ma 100Greater thanMa 2008.622
OpenGreater thanClose9.140
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Lyra Therapeutics Inc

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Fundamental data was last updated by Penke on 2025-06-19 11:41:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Lyra Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -4,670.5% means that $-46.70 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lyra Therapeutics Inc:

  • The MRQ is -4,670.5%. The company is making a huge loss. -2
  • The TTM is -6,015.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-4,670.5%TTM-6,015.2%+1,344.8%
TTM-6,015.2%YOY-5,222.0%-793.2%
TTM-6,015.2%5Y-13,499.7%+7,484.5%
5Y-13,499.7%10Y-12,272.5%-1,227.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,670.5%-92.7%-4,577.8%
TTM-6,015.2%-141.4%-5,873.8%
YOY-5,222.0%-186.1%-5,035.9%
3Y-15,498.2%-248.3%-15,249.9%
5Y-13,499.7%-338.6%-13,161.1%
10Y-12,272.5%-488.9%-11,783.6%
4.3.1.2. Return on Assets

Shows how efficient Lyra Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • -15.2% Return on Assets means that Lyra Therapeutics Inc generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lyra Therapeutics Inc:

  • The MRQ is -15.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -24.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.2%TTM-24.4%+9.2%
TTM-24.4%YOY-13.0%-11.4%
TTM-24.4%5Y-15.2%-9.2%
5Y-15.2%10Y-15.6%+0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.2%-11.5%-3.7%
TTM-24.4%-11.6%-12.8%
YOY-13.0%-11.4%-1.6%
3Y-16.9%-11.8%-5.1%
5Y-15.2%-12.1%-3.1%
10Y-15.6%-13.8%-1.8%
4.3.1.3. Return on Equity

Shows how efficient Lyra Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • -220.7% Return on Equity means Lyra Therapeutics Inc generated $-2.21 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lyra Therapeutics Inc:

  • The MRQ is -220.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -132.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-220.7%TTM-132.1%-88.6%
TTM-132.1%YOY-20.1%-112.0%
TTM-132.1%5Y-41.0%-91.1%
5Y-41.0%10Y-40.0%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-220.7%-13.6%-207.1%
TTM-132.1%-14.9%-117.2%
YOY-20.1%-14.4%-5.7%
3Y-56.6%-17.0%-39.6%
5Y-41.0%-17.9%-23.1%
10Y-40.0%-20.1%-19.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Lyra Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Lyra Therapeutics Inc is operating .

  • Measures how much profit Lyra Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -4,901.1% means the company generated $-49.01  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lyra Therapeutics Inc:

  • The MRQ is -4,901.1%. The company is operating very inefficient. -2
  • The TTM is -4,373.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-4,901.1%TTM-4,373.5%-527.6%
TTM-4,373.5%YOY-5,509.7%+1,136.2%
TTM-4,373.5%5Y-13,099.9%+8,726.4%
5Y-13,099.9%10Y-11,909.0%-1,190.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,901.1%-229.2%-4,671.9%
TTM-4,373.5%-250.3%-4,123.2%
YOY-5,509.7%-205.1%-5,304.6%
3Y-14,769.6%-220.2%-14,549.4%
5Y-13,099.9%-342.6%-12,757.3%
10Y-11,909.0%-475.5%-11,433.5%
4.3.2.2. Operating Ratio

Measures how efficient Lyra Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 49.31 means that the operating costs are $49.31 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 49.311. The company is inefficient in keeping operating costs low. -1
  • The TTM is 55.603. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ49.311TTM55.603-6.292
TTM55.603YOY67.719-12.116
TTM55.6035Y159.938-104.335
5Y159.93810Y145.398+14.540
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ49.3112.110+47.201
TTM55.6032.704+52.899
YOY67.7193.063+64.656
3Y158.0853.576+154.509
5Y159.9384.713+155.225
10Y145.3986.512+138.886
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Lyra Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Lyra Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.96 means the company has $2.96 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 2.956. The company is able to pay all its short-term debts. +1
  • The TTM is 3.401. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.956TTM3.401-0.445
TTM3.401YOY5.990-2.589
TTM3.4015Y8.173-4.772
5Y8.17310Y7.832+0.342
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9563.661-0.705
TTM3.4013.786-0.385
YOY5.9904.121+1.869
3Y5.9314.680+1.251
5Y8.1735.765+2.408
10Y7.8326.150+1.682
4.4.3.2. Quick Ratio

Measures if Lyra Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 2.77 means the company can pay off $2.77 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 2.767. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.160. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.767TTM4.160-1.393
TTM4.160YOY9.947-5.787
TTM4.1605Y9.409-5.249
5Y9.40910Y8.950+0.459
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7672.826-0.059
TTM4.1603.128+1.032
YOY9.9473.782+6.165
3Y8.1764.304+3.872
5Y9.4095.703+3.706
10Y8.9506.454+2.496
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Lyra Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Lyra Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lyra Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.93 means that Lyra Therapeutics Inc assets are financed with 93.1% credit (debt) and the remaining percentage (100% - 93.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 0.931. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.792. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.931TTM0.792+0.139
TTM0.792YOY0.336+0.456
TTM0.7925Y0.353+0.439
5Y0.35310Y0.531-0.178
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9310.324+0.607
TTM0.7920.347+0.445
YOY0.3360.327+0.009
3Y0.4530.339+0.114
5Y0.3530.349+0.004
10Y0.5310.382+0.149
4.5.4.2. Debt to Equity Ratio

Measures if Lyra Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 1,354.4% means that company has $13.54 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 13.544. The company is unable to pay all its debts with equity. -1
  • The TTM is 5.785. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ13.544TTM5.785+7.759
TTM5.785YOY0.532+5.253
TTM5.7855Y1.443+4.342
5Y1.44310Y1.359+0.084
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.5440.383+13.161
TTM5.7850.436+5.349
YOY0.5320.410+0.122
3Y2.2080.446+1.762
5Y1.4430.460+0.983
10Y1.3590.509+0.850
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Lyra Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of 0.00 means the investor is paying $0.00 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lyra Therapeutics Inc:

  • The EOD is -0.361. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.005. Based on the earnings, the company is expensive. -2
  • The TTM is -0.005. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.361MRQ-0.005-0.356
MRQ-0.005TTM-0.005+0.000
TTM-0.005YOY-3.952+3.947
TTM-0.0055Y-2.691+2.686
5Y-2.69110Y-2.446-0.245
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.361-2.197+1.836
MRQ-0.005-2.027+2.022
TTM-0.005-2.527+2.522
YOY-3.952-3.733-0.219
3Y-2.104-3.717+1.613
5Y-2.691-6.036+3.345
10Y-2.446-6.649+4.203
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lyra Therapeutics Inc:

  • The EOD is -0.349. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.005. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.005. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.349MRQ-0.005-0.344
MRQ-0.005TTM-0.005+0.000
TTM-0.005YOY-3.713+3.708
TTM-0.0055Y-2.209+2.204
5Y-2.20910Y-2.008-0.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.349-3.007+2.658
MRQ-0.005-2.704+2.699
TTM-0.005-3.627+3.622
YOY-3.713-4.334+0.621
3Y-2.332-5.070+2.738
5Y-2.209-8.532+6.323
10Y-2.008-9.305+7.297
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Lyra Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.04 means the investor is paying $0.04 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lyra Therapeutics Inc:

  • The EOD is 3.187. Based on the equity, the company is fair priced.
  • The MRQ is 0.043. Based on the equity, the company is cheap. +2
  • The TTM is 0.024. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD3.187MRQ0.043+3.144
MRQ0.043TTM0.024+0.019
TTM0.024YOY3.239-3.215
TTM0.0245Y1.696-1.672
5Y1.69610Y1.542+0.154
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.1871.921+1.266
MRQ0.0431.843-1.800
TTM0.0242.113-2.089
YOY3.2392.467+0.772
3Y1.5932.541-0.948
5Y1.6963.666-1.970
10Y1.5424.311-2.769
4.6.2. Total Gains per Share

2.4. Latest News of Lyra Therapeutics Inc

Does Lyra Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Lyra Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-27
18:52
Lyra Therapeutics Raises $5 Mln In Direct Offering, Eyes $9.8 Mln Via Warrant ExercisesRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lyra Therapeutics Inc.

4.8.1. Institutions holding Lyra Therapeutics Inc

Institutions are holding 48.647% of the shares of Lyra Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Perceptive Advisors LLC19.25170.05661275756200
2025-03-31BlackRock Inc4.555803018986-90812-2.9202
2025-03-31Vanguard Group Inc2.664301765585-21837-1.2217
2025-03-31Samsara BioCapital, LLC2.09780.03131390130-575559-29.2803
2025-03-31Ikarian Capital, LLC1.59680.0165105814800
2025-03-31Geode Capital Management, LLC1.53320101600413003814.6775
2025-03-31ADAR1 Capital Management LLC0.80460.012553320000
2025-03-31State Street Corp0.7375048872000
2024-12-31UBS Group AG0.641304249654000501605.6592
2025-03-31Goldman Sachs Group Inc0.55860370194-185314-33.3594
2025-03-31Two Sigma Advisers, LLC0.550.0001364478-21022-5.4532
2025-03-31Northern Trust Corp0.50203326394632916.1814
2025-03-31BNP Paribas Arbitrage, SA0.3660242546-2374-0.9693
2025-03-31BOOTHBAY FUND MANAGEMENT, LLC0.35310.000823398900
2025-03-31Susquehanna International Group, LLP0.32830217567114137110.3519
2025-03-31Two Sigma Investments LLC0.29150.0001193145-16852-8.0249
2025-03-31New York State Common Retirement Fund0.2336015480000
2025-03-31Charles Schwab Investment Management Inc0.1684011160900
2025-03-31Rhumbline Advisers0.132408771046452112.5891
2025-03-31Bank of New York Mellon Corp0.108071585-4381-5.7671
Total 37.47490.117924833562-181145-0.7%

4.9.2. Funds holding Lyra Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv1.4978099254300
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr0.68790.000145583200
2025-03-31Fidelity Small Cap Index0.47850.000231710000
2025-04-30Fidelity Extended Market Index0.41190.0001272931-1598-0.5821
2025-04-30Vanguard Russell 2000 ETF0.36230.0002240117134895.952
2024-09-30Russell 3000 Screened Index Composite0.28170.00351867001867000
2025-04-30Spartan Total Market Index Pool G0.21150.000114013300
2025-04-30Schwab Small Cap Index0.16840.000211160900
2025-03-31NT R2000 Index Fund - NL0.14230.00029429779719546.8446
2025-03-31NT R2000 Index Fund - DC - NL - 30.11370.00027533163438533.4062
2025-04-30Spartan Extended Market Index Pool F0.10770.00017135015982.291
2025-03-31Extended Equity Market Fund K0.10640.0001704782160.3074
2025-03-31Northern Small Cap Index0.09880.000765440654400
2025-04-30Fidelity Series Total Market Index0.095106300600
2025-03-31State Street Russell 2000 Value CIT0.09080.001260200602000
2025-04-30Fidelity Total Market Index0.089905956000
2025-03-31Russell Personalized DI All Cap SMA0.072304793200
2025-05-31iShares Russell 2000 ETF3.3790.00044478300
2025-03-31Spartan Small Cap Index Pool K0.06710.00034448400
2025-03-31LVIP SSgA Small Cap Index Std0.05720.00033790000
Total 8.52030.00793451726+469202+13.6%

5.3. Insider Transactions

Insiders are holding 0.829% of the shares of Lyra Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-10Harlan WaksalBUY500148
2023-05-31Nbvm Gp, LlcBUY36108121.5
2023-05-31Perceptive Advisors LlcBUY72216124.5
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets56,316
Total Liabilities52,444
Total Stockholder Equity3,872
 As reported
Total Liabilities 52,444
Total Stockholder Equity+ 3,872
Total Assets = 56,316

Assets

Total Assets56,316
Total Current Assets33,905
Long-term Assets22,411
Total Current Assets
Cash And Cash Equivalents 31,735
Other Current Assets 2,170
Total Current Assets  (as reported)33,905
Total Current Assets  (calculated)33,905
+/-0
Long-term Assets
Property Plant Equipment 20,418
Long-term Assets Other 1,993
Long-term Assets  (as reported)22,411
Long-term Assets  (calculated)22,411
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities11,470
Long-term Liabilities40,974
Total Stockholder Equity3,872
Total Current Liabilities
Short-term Debt 4,243
Accounts payable 725
Other Current Liabilities 6,286
Total Current Liabilities  (as reported)11,470
Total Current Liabilities  (calculated)11,254
+/- 216
Long-term Liabilities
Capital Lease Obligations 33,356
Long-term Liabilities  (as reported)40,974
Long-term Liabilities  (calculated)33,356
+/- 7,618
Total Stockholder Equity
Common Stock66
Retained Earnings -413,337
Other Stockholders Equity 417,143
Total Stockholder Equity (as reported)3,872
Total Stockholder Equity (calculated)3,872
+/-0
Other
Capital Stock66
Cash and Short Term Investments 31,735
Common Stock Shares Outstanding 1,315
Current Deferred Revenue216
Liabilities and Stockholders Equity 56,316
Net Debt 1,621
Net Invested Capital 3,872
Net Working Capital 22,435
Property Plant and Equipment Gross 24,675
Short Long Term Debt Total 33,356



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
14,963
40,766
92,723
87,330
80,830
72,917
76,332
67,762
54,867
47,345
130,035
119,463
109,968
93,868
125,675
120,575
142,600
141,527
94,582
78,756
66,346
56,316
56,31666,34678,75694,582141,527142,600120,575125,67593,868109,968119,463130,03547,34554,86767,76276,33272,91780,83087,33092,72340,76614,963000
   > Total Current Assets 
23,888
0
0
10,119
35,540
89,310
83,555
75,917
67,351
70,073
60,886
47,918
40,555
122,381
112,230
100,829
84,799
118,253
104,920
104,821
89,443
69,435
54,444
43,025
33,905
33,90543,02554,44469,43589,443104,821104,920118,25384,799100,829112,230122,38140,55547,91860,88670,07367,35175,91783,55589,31035,54010,1190023,888
       Cash And Cash Equivalents 
-23,888
0
0
9,808
35,247
86,599
81,555
74,593
66,105
69,046
58,131
45,747
33,755
120,669
109,558
32,550
22,019
54,361
24,850
22,353
15,799
31,905
23,800
40,577
31,735
31,73540,57723,80031,90515,79922,35324,85054,36122,01932,550109,558120,66933,75545,74758,13169,04666,10574,59381,55586,59935,2479,80800-23,888
       Short-term Investments 
47,776
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65,344
60,688
61,789
77,700
80,400
71,319
35,593
27,826
0
0
0027,82635,59371,31980,40077,70061,78960,68865,3440000000000000047,776
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
5,000
0
0
0
0
0
0
0
0
0
0
0
0
0000000000005,000000000000000
       Other Current Assets 
0
0
0
311
586
5,422
4,000
2,648
1,246
2,054
5,510
4,342
1,800
1,712
2,672
2,935
2,092
3,903
2,370
2,068
2,325
1,937
2,818
2,448
2,170
2,1702,4482,8181,9372,3252,0682,3703,9032,0922,9352,6721,7121,8004,3425,5102,0541,2462,6484,0005,422586311000
   > Long-term Assets 
-23,888
0
0
4,844
5,226
3,413
3,775
4,913
5,566
6,259
6,876
6,949
6,790
7,654
7,233
9,139
9,069
7,422
15,655
37,779
52,084
25,147
24,312
23,321
22,411
22,41123,32124,31225,14752,08437,77915,6557,4229,0699,1397,2337,6546,7906,9496,8766,2595,5664,9133,7753,4135,2264,84400-23,888
       Property Plant Equipment 
0
0
0
3,419
3,247
3,084
3,446
4,466
5,237
5,687
6,302
5,858
5,384
4,869
4,361
4,466
3,829
1,980
6,800
35,276
49,409
23,155
22,320
21,328
20,418
20,41821,32822,32023,15549,40935,2766,8001,9803,8294,4664,3614,8695,3845,8586,3025,6875,2374,4663,4463,0843,2473,419000
       Long-term Assets Other 
-23,888
0
0
1,425
1,979
329
329
447
329
243
245
762
1,077
1,696
2,872
3,281
5,240
4,353
7,463
1,111
683
1,992
1,992
1,993
1,993
1,9931,9931,9921,9926831,1117,4634,3535,2403,2812,8721,6961,0777622452433294473293291,9791,42500-23,888
> Total Liabilities 
0
0
0
7,635
167,547
5,900
6,416
6,338
5,366
18,833
20,574
20,551
19,189
19,005
26,241
29,214
27,777
27,098
36,336
53,180
64,023
63,605
58,137
54,752
52,444
52,44454,75258,13763,60564,02353,18036,33627,09827,77729,21426,24119,00519,18920,55120,57418,8335,3666,3386,4165,900167,5477,635000
   > Total Current Liabilities 
0
0
0
5,208
5,158
3,942
4,708
4,884
4,170
5,904
17,773
18,246
17,802
9,872
13,605
14,470
14,154
14,111
19,235
19,597
18,724
19,276
14,954
12,631
11,470
11,47012,63114,95419,27618,72419,59719,23514,11114,15414,47013,6059,87217,80218,24617,7735,9044,1704,8844,7083,9425,1585,208000
       Short-term Debt 
0
0
0
899
1,838
1,886
1,928
985
1,007
1,029
2,104
1,074
2,194
1,852
1,308
3,510
1,900
3,376
2,806
10,868
4,504
8,538
4,003
4,121
4,243
4,2434,1214,0038,5384,50410,8682,8063,3761,9003,5101,3081,8522,1941,0742,1041,0291,0079851,9281,8861,838899000
       Accounts payable 
0
0
0
1,069
1,358
1,146
530
922
1,169
1,899
2,912
3,125
2,408
1,670
2,900
2,616
3,951
4,188
5,054
3,131
2,844
4,971
2,292
1,179
725
7251,1792,2924,9712,8443,1315,0544,1883,9512,6162,9001,6702,4083,1252,9121,8991,1699225301,1461,3581,069000
       Other Current Liabilities 
0
0
0
3,240
1,962
910
2,250
2,977
1,994
2,976
2,916
4,258
3,140
4,539
6,667
9,030
6,793
5,050
9,649
3,940
10,057
4,953
8,052
6,933
6,286
6,2866,9338,0524,95310,0573,9409,6495,0506,7939,0306,6674,5393,1404,2582,9162,9761,9942,9772,2509101,9623,240000
   > Long-term Liabilities 
0
0
0
2,427
162,389
1,958
1,708
1,454
1,196
12,929
2,801
2,305
1,387
9,133
12,636
14,744
13,623
12,987
17,101
33,583
45,299
44,329
43,183
42,121
40,974
40,97442,12143,18344,32945,29933,58317,10112,98713,62314,74412,6369,1331,3872,3052,80112,9291,1961,4541,7081,958162,3892,427000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
12,000
2,145
1,926
1,288
9,130
12,633
14,077
0
12,987
0
0
0
0
0
0
0
000000012,987014,07712,6339,1301,2881,9262,14512,000000000000
       Deferred Long Term Liability 
0
0
0
0
1,650
0
0
0
0
12,000
0
0
1,288
9,130
13,176
0
13,432
0
0
0
0
0
0
0
0
0000000013,432013,1769,1301,2880012,00000001,6500000
> Total Stockholder Equity
23,279
0
0
7,328
-126,781
86,823
80,914
74,492
67,551
57,499
47,188
34,316
28,156
111,030
93,222
80,754
66,091
98,577
84,239
89,420
77,504
30,977
20,619
11,594
3,872
3,87211,59420,61930,97777,50489,42084,23998,57766,09180,75493,222111,03028,15634,31647,18857,49967,55174,49280,91486,823-126,7817,3280023,279
   Common Stock
0
0
0
6
-39,742
13
13
13
13
13
13
13
13
32
32
32
32
50
50
57
61
65
65
65
66
6665656561575050323232321313131313131313-39,7426000
   Retained Earnings -413,337-404,790-393,811-381,938-333,807-311,355-296,199-280,548-264,930-248,675-234,440-214,893-200,409-193,397-179,780-168,725-157,686-149,884-142,863-136,529-131,989-127,757000
   Capital Surplus 
0
0
0
0
5,208
0
0
224,363
225,224
226,211
0
0
228,552
325,891
325,891
0
331,001
0
0
0
0
0
0
0
0
00000000331,0010325,891325,891228,55200226,211225,224224,363005,2080000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
0
0
0
4,419
-34,534
223,339
223,764
224,363
225,224
226,211
226,955
227,700
228,552
325,891
327,630
329,387
331,001
379,102
380,395
400,685
411,225
412,854
414,345
416,319
417,143
417,143416,319414,345412,854411,225400,685380,395379,102331,001329,387327,630325,891228,552227,700226,955226,211225,224224,363223,764223,339-34,5344,419000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,534
Cost of Revenue-471
Gross Profit1,0631,063
 
Operating Income (+$)
Gross Profit1,063
Operating Expense-97,882
Operating Income-96,348-96,819
 
Operating Expense (+$)
Research Development43,766
Selling General Administrative18,501
Selling And Marketing Expenses0
Operating Expense97,88262,267
 
Net Interest Income (+$)
Interest Income2,952
Interest Expense-0
Other Finance Cost-0
Net Interest Income2,952
 
Pretax Income (+$)
Operating Income-96,348
Net Interest Income2,952
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-93,396-99,300
EBIT - interestExpense = -60,733
-93,396
-93,435
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-60,733-93,396
Earnings Before Interest and Taxes (EBITDA)-60,262
 
After tax Income (+$)
Income Before Tax-93,396
Tax Provision-39
Net Income From Continuing Ops-93,435-93,435
Net Income-93,435
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses97,882
Total Other Income/Expenses Net2,952-2,952
 

Technical Analysis of Lyra Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lyra Therapeutics Inc. The general trend of Lyra Therapeutics Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lyra Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Lyra Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lyra Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 9.81 < 37.50 < 125.00.

The bearish price targets are: 8.4 > 6.25 > 4.1.

Know someone who trades $LYRA? Share this with them.👇

Lyra Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lyra Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lyra Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lyra Therapeutics Inc. The current macd is -0.2551954.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lyra Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Lyra Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Lyra Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Lyra Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartLyra Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lyra Therapeutics Inc. The current adx is 29.94.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Lyra Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Lyra Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lyra Therapeutics Inc. The current sar is 26.44.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Lyra Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lyra Therapeutics Inc. The current rsi is 45.01. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Lyra Therapeutics Inc Daily Relative Strength Index (RSI) ChartLyra Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lyra Therapeutics Inc. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lyra Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Lyra Therapeutics Inc Daily Stochastic Oscillator ChartLyra Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lyra Therapeutics Inc. The current cci is -75.89865689.

Lyra Therapeutics Inc Daily Commodity Channel Index (CCI) ChartLyra Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lyra Therapeutics Inc. The current cmo is -18.59199816.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Lyra Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartLyra Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lyra Therapeutics Inc. The current willr is -85.29862175.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Lyra Therapeutics Inc Daily Williams %R ChartLyra Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lyra Therapeutics Inc. The current atr is 2.45457797.

Lyra Therapeutics Inc Daily Average True Range (ATR) ChartLyra Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lyra Therapeutics Inc. The current obv is 28,139,948.

Lyra Therapeutics Inc Daily On-Balance Volume (OBV) ChartLyra Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lyra Therapeutics Inc. The current mfi is 22.60.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Lyra Therapeutics Inc Daily Money Flow Index (MFI) ChartLyra Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lyra Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-03ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-23MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Lyra Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lyra Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.013
Ma 20Greater thanMa 5013.604
Ma 50Greater thanMa 1009.229
Ma 100Greater thanMa 2008.622
OpenGreater thanClose9.140
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Lyra Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Lyra Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lyra Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lyra Therapeutics Inc

I send you an email if I find something interesting about Lyra Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Lyra Therapeutics Inc.

Receive notifications about Lyra Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.